Display options
Cite
Reid IR, Brown JP, Levitt N, et al. Re-treatment of relapsed Paget's disease of bone with zoledronic acid: results from an open-label study. Bonekey Rep. 2013;2:442doi: 10.1038/bonekey.2013.176.
Reid, I. R., Brown, J. P., Levitt, N., Román Ivorra, J. A., Bachiller-Corral, J., Ross, I. L., Su, G., Antunez-Flores, O., & Aftring, R. P. (2013). Re-treatment of relapsed Paget's disease of bone with zoledronic acid: results from an open-label study. BoneKEy reports, 2442. https://doi.org/10.1038/bonekey.2013.176
Reid, Ian R, et al. "Re-treatment of relapsed Paget's disease of bone with zoledronic acid: results from an open-label study." BoneKEy reports vol. 2 (2013): 442. doi: https://doi.org/10.1038/bonekey.2013.176
Reid IR, Brown JP, Levitt N, Román Ivorra JA, Bachiller-Corral J, Ross IL, Su G, Antunez-Flores O, Aftring RP. Re-treatment of relapsed Paget's disease of bone with zoledronic acid: results from an open-label study. Bonekey Rep. 2013 Nov 06;2:442. doi: 10.1038/bonekey.2013.176. eCollection 2013. PMID: 24422139; PMCID: PMC3844974.
Copy Download .nbib Format: NLM
Share it on

Bonekey Rep. 2013 Nov 06;2:442. doi: 10.1038/bonekey.2013.176. eCollection 2013.

Re-treatment of relapsed Paget's disease of bone with zoledronic acid: results from an open-label study.

BoneKEy reports

Ian R Reid, Jacques P Brown, Naomi Levitt, José A Román Ivorra, Javier Bachiller-Corral, Ian L Ross, Guoqin Su, Oscar Antunez-Flores, R Paul Aftring

Affiliations

  1. Faculty of Medical and Health Sciences, University of Auckland , Auckland, New Zealand.
  2. Department of Medicine, Laval University , Quebec City, Quebec, Canada.
  3. Department of Medicine, University of Cape Town , Observatory, South Africa.
  4. Servicio de Reumatología, Hospital Universitario y Politécnico La Fe , Valencia, Spain.
  5. Servicio de Reumatología, Hospital Ramon Y Cajal , Madrid, Spain.
  6. Novartis Pharmaceuticals Corporation , East Hanover, NJ, USA.

PMID: 24422139 PMCID: PMC3844974 DOI: 10.1038/bonekey.2013.176

Abstract

Six patients from the phase 3 trials of zoledronic acid in Paget's disease, who had received zoledronic acid initially and had subsequently relapsed, were entered into an open re-treatment study. Following re-treatment, each patient reached similar absolute nadirs of serum alkaline phosphatase to those recorded after their first dose. No significant adverse events were reported. It is concluded that, while re-treatment of Paget's disease with zoledronic acid is rarely needed, it is safe and effective, with no evidence of treatment resistance based on this small cohort.

References

  1. N Engl J Med. 1997 Feb 20;336(8):558-66 - PubMed
  2. J Clin Endocrinol Metab. 2010 Sep;95(9):4380-7 - PubMed
  3. J Bone Miner Res. 1997 Apr;12(4):691-2 - PubMed
  4. Am J Med. 1999 May;106(5):513-20 - PubMed
  5. J Bone Miner Res. 2011 Sep;26(9):2261-70 - PubMed
  6. Am J Med. 1996 Oct;101(4):341-8 - PubMed
  7. Clin Orthop Relat Res. 1987 Apr;(217):79-98 - PubMed
  8. N Engl J Med. 2005 Sep 1;353(9):898-908 - PubMed
  9. J Bone Miner Res. 1999 Oct;14 Suppl 2:79-84 - PubMed
  10. J Bone Miner Res. 2001 Aug;16(8):1379-87 - PubMed
  11. Lancet. 1985 Jun 29;1(8444):1474-7 - PubMed

Publication Types